Skip to main content
. Author manuscript; available in PMC: 2013 Sep 11.
Published in final edited form as: Leuk Lymphoma. 2012 Dec 31;54(8):1658–1664. doi: 10.3109/10428194.2012.751528

Table III.

Univariate Analysis for Progression Free Survival and Overall Survival

PFS variable HR p-value
Number of prev therapy
>1 vs 1
1.60 0.02
Pre-SCT response
Others vs. CR+VGPR
1.67 0.018
Post-SCT response
Others vs. CR+VGPR
2.79 <0.001
Pre-SCT response
Others vs. CR
2.49 0.015
Post-SCT response
Others vs. CR
3.63 <0.001
Durie salmon
3 vs.1 or 2
1.80 0.033
Complex Karyotype
No vs. yes
0.63 0.042
Del 13 Karyotype
No. vs. yes
0.56 0.035
High risk FISH/Karyotype
No vs. yes
0.65 0.041
ISS
1 vs. 2/3
1 vs. 2: 0.89
1vs. 3: 0.49
2 vs. 3: 0.56
0.038
OS Variable
Pre-SCT response
Others vs. CR
1.74 0.35
Post-SCT response
Others vs. CR
3.10 0.0043
Del 13 Karyotype
No vs. yes
0.44 0.045
HD
No vs. yes
0.36 0.018

HR stands for hazard ratio; prev previous; SCT stem cell transplant; CR complete response; VGPR very good partial response; PR partial response; SD stable disease; NRM non relapse mortality; OS overall survival; PFS progression free survival; FISH florescent in-situ hybridization; ISS international scoring system; HD hemodialysis.